

June 2019 Medical Policies and Clinical Utilization Management Guidelines update

Published: Oct 1, 2019 - **State & Federal** / Medicare

The *Medical Policies* and *Clinical Utilization Management (UM) Guidelines* below were developed or revised to support clinical coding edits. Several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed. **Please note:** The *Medical Policies* and *Clinical UM Guidelines* below are followed in the absence of Medicare guidance.

Please share this notice with other members of your practice and office staff.

To view a guideline, visit the provider website at www.anthem.com/medicareprovider.

Notes/updates

Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive:

- DME.00037 — added devices that combine cooling and vibration to the investigational and not medically necessary statement
- LAB.00027 — added Mediator Release Test to investigational and not medically necessary statement
- LAB.00033 — clarified investigational and not medically necessary statement to include 4K score and AR-V7
- OR-PR.00003:
 - Clarified medically necessary position statement criteria 2 through 4
 - Added statement that use of prosthetic devices that combine both a microprocessor controlled knee and foot-ankle prosthesis is considered investigational and not medically necessary for all indications
- SURG.00011:

- Added new medically necessary and investigational and not medically necessary statements addressing amniotic membrane-derived products for conjunctival and corneal indications, including KeraSys and Prokera
- Added new products to investigational and not medically necessary statement
- SURG.00045:
 - Added erectile dysfunction, Peyronie’s disease and wound repair to the investigational and not medically necessary statement
 - Revised title
- SURG.00121 — added investigational and not medically necessary statement to address use of transcatheter tricuspid valve repair or replacement for all indications

The following AIM Specialty Health® updates were approved on June 6, 2019:

- Advanced imaging:
 - Imaging of the heart
 - Oncologic imaging
 - Vascular imaging
 - Proton beam therapy
 - Rehabilitative therapies — physical therapy, occupational therapy and speech therapy (new)

Medical Policies

On June 6, 2019, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following *Medical Policies* applicable to Anthem Blue Cross and Blue Shield (Anthem).

Publish date	<i>Medical Policy</i>	<i>Medical Policy title</i>	New or revised
June 13, 2019	MED.00129	Gene Therapy for Spinal Muscular Atrophy	New
June 13, 2019	GENE.00029	Genetic Testing for Breast and/or Ovarian Cancer Syndrome	Revised
June 13, 2019	* SURG.00011	Allogeneic, Xenographic, Synthetic,	Revised

		and Composite Products for Wound Healing and Soft Tissue Grafting	
June 13, 2019	SURG.00023	Breast Procedures; including Reconstructive Surgery, Implants and Other Breast Procedures	Revised
June 13, 2019	SURG.00028	Surgical and Minimally Invasive Treatments for Benign Prostatic Hyperplasia (BPH) and Other Genitourinary Conditions	Revised
June 27, 2019	GENE.00025	Molecular Profiling and Proteogenomic Testing for the Evaluation of Malignancies Previous title: Molecular Profiling and Proteogenomic Testing for the Evaluation of Malignant Tumors	Revised
June 27, 2019	DRUG.00046	Ipilimumab (Yervoy®)	Revised
June 27, 2019	DRUG.00053	Carfilzomib (Kyprolis®)	Revised
June 27, 2019	DRUG.00062	Obinutuzumab (Gazyva®)	Revised
June 27, 2019	DRUG.00067	Ramucirumab (Cyramza®)	Revised
June 27, 2019	DRUG.00071	Pembrolizumab (Keytruda®)	Revised
June 27, 2019	DRUG.00075	Nivolumab (Opdivo®)	Revised
June 27, 2019	DRUG.00107	Avelumab (Bavencio®)	Revised
June 27, 2019	GENE.00044	Analysis of PIK3CA Status in Tumor Cells	Revised
June 27, 2019	* SURG.00121	Transcatheter Heart Valve Procedures	Revised
June 27, 2019	GENE.00001	Genetic Testing for Cancer Susceptibility	Revised
June 27, 2019	GENE.00043	Genetic Testing of an Individual's Genome for Inherited Diseases	Revised
June 27, 2019	LAB.00011	Analysis of Proteomic Patterns	Revised
June 27, 2019	LAB.00015	Detection of Circulating Tumor Cells in the Blood as a Prognostic Factor for Cancer	Revised
July 10, 2019	GENE.00051	Bronchial Gene Expression Classification for the Diagnostic Evaluation of Lung Cancer	New
July 10, 2019	SURG.00153	Cardiac Contractility Modulation Therapy	New
July 10, 2019	* DME.00037	Cooling Devices and Combined	Revised

		Cooling/Heating Devices	
July 10, 2019	DME.00038	Static Progressive Stretch (SPS) and Patient-Actuated Serial Stretch (PASS) Devices	Revised
July 10, 2019	GENE.00011	Gene Expression Profiling for Managing Breast Cancer Treatment	Revised
July 10, 2019	* LAB.00027	Selected Blood, Serum and Cellular Allergy and Toxicity Tests	Revised
July 10, 2019	* LAB.00033	Protein Biomarkers for the Screening, Detection and Management of Prostate Cancer	Revised
July 10, 2019	MED.00109	Corneal Collagen Cross-Linking	Revised
July 10, 2019	* OR-PR.00003	Microprocessor Controlled Lower Limb Prosthesis	Revised
July 10, 2019	SURG.00005	Partial Left Ventriculectomy	Revised
July 10, 2019	* SURG.00045	Extracorporeal Shock Wave Therapy Previous Title: Extracorporeal Shock Wave Therapy for Orthopedic Conditions	Revised
July 10, 2019	SURG.00120	Internal Rib Fixation Systems	Revised
September 4, 2019	GENE.00010	Genotype Panel Testing for Genetic Polymorphisms to Determine Drug-Metabolizer Status Previous title: Genotype Testing for Genetic Polymorphisms to Determine Drug-Metabolizer Status	Revised

Clinical UM Guidelines

On June 6, 2019, the MPTAC approved the following *Clinical UM Guidelines* applicable to Anthem. These guidelines were adopted by the Medical Operations Committee for Medicare Advantage members on July 5, 2019.

Publish date	Clinical UM Guideline #	Clinical UM Guideline title	New or revised
June 27, 2019	CG-SURG-97	Cardioverter Defibrillators	New
June 27, 2019	CG-DRUG-98	Bendamustine Hydrochloride	Revised
June 27, 2019	CG-LAB-09	Drug Testing or Screening in the Context of Substance Use Disorder and Chronic Pain	Revised
June 27, 2019	CG-LAB-14	Respiratory Viral Panel Testing in the	Revised

		Outpatient Setting	
July 10, 2019	CG-SURG-100	Laser Trabeculoplasty and Laser Peripheral Iridotomy	New
July 10, 2019	CG-ADMIN-01	Clinical Utilization Management (UM) Guideline for Pre-Payment Review Medical Necessity Determinations When No Other Clinical UM Guideline Exists	Revised
July 10, 2019	CG-ANC-06	Ambulance Services: Ground; Non-Emergent	Revised
July 10, 2019	CG-DME-03	Neuromuscular Stimulation in the Treatment of Muscle Atrophy	Revised
July 10, 2019	CG-DME-07	Augmentative and Alternative Communication (AAC) Devices with Digitized or Synthesized Speech Output Previous title: Augmentative and Alternative Communication (AAC) Devices/Speech Generating Devices (SGD)	Revised
July 10, 2019	CG-DME-08	Infant Home Apnea Monitors	Revised
July 10, 2019	CG-DME-39	Dynamic Low-Load Prolonged-Duration Stretch Devices	Revised
July 10, 2019	CG-DME-42	Non-implantable Insulin Infusion and Blood Glucose Monitoring Devices	Revised
July 10, 2019	CG-DME-45	Ultrasound Bone Growth Stimulation	Revised
July 10, 2019	CG-MED-41	Moderate to Deep Anesthesia Services for Dental Surgery in the Facility Setting	Revised
July 10, 2019	CG-MED-49	Auditory Brainstem Responses (ABRs) and Evoked Otoacoustic Emissions (OAEs) for Hearing Disorders	Revised
July 10, 2019	CG-MED-57	Cardiac Stress Testing with Electrocardiogram	Revised
July 10, 2019	CG-MED-59	Upper Gastrointestinal Endoscopy in Adults	Revised
July 10, 2019	CG-SURG-11	Surgical Treatment for Dupuytren's Contracture	Revised
July 10, 2019	CG-SURG-17	Trigger Point Injections	Revised
July 10, 2019	CG-SURG-35	Intracytoplasmic Sperm Injection	Revised

		(ICSI)	
July 10, 2019	CG-SURG-49	Endovascular Techniques (Percutaneous or Open Exposure) for Arterial Revascularization of the Lower Extremities	Revised
July 10, 2019	CG-SURG-81	Cochlear Implants and Auditory Brainstem Implants	Revised
July 10, 2019	CG-SURG-85	Hip Resurfacing	Revised
July 10, 2019	CG-SURG-93	Angiographic Evaluation and Endovascular Intervention for Dialysis Access Circuit Dysfunction	Revised
September 4, 2019	CG-GENE-11	Genotype Testing for Individual Genetic Polymorphisms to Determine Drug-Metabolizer Status	New
September 4, 2019	CG-GENE-10	Chromosomal Microarray Analysis (CMA) for Developmental Delay, Autism Spectrum Disorder, Intellectual Disability (Intellectual Developmental Disorder) and Congenital Anomalies	New
September 4, 2019	CG-SURG-101	Ablative Techniques as a Treatment for Barrett's Esophagus	New
September 4, 2019	CG-SURG-102	Alcohol Septal Ablation for Treatment of Hypertrophic Cardiomyopathy	New

503273MUPENMUB

URL: <https://providernews.anthem.com/indiana/article/june-2019-medical-policies-and-clinical-utilization-management-guidelines-update-1>

Featured In:

October 2019 Anthem Provider News - Indiana, October 2019 Anthem Provider News - Kentucky, October 2019 Anthem Provider News - Missouri, October 2019 Anthem Provider News - Wisconsin, October 2019 Anthem Provider News - Ohio

Anthem Blue Cross and Blue Shield is the trade name of: In Colorado Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. In Connecticut: Anthem Health Plans, Inc. In Georgia: Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. In Indiana: Anthem Insurance Companies, Inc. In Kentucky: Anthem Health Plans of Kentucky, Inc. In Maine: Anthem Health Plans of Maine, Inc. In Missouri (excluding 30 counties in the Kansas City area): RightCHOICE® Managed Care, Inc. (RIT), Healthy Alliance® Life Insurance Company (HALIC), and HMO Missouri, Inc. RIT and certain affiliates administer non-HMO benefits underwritten by HALIC and HMO benefits underwritten by HMO Missouri, Inc. RIT and certain affiliates only provide administrative services for self-funded plans and do not underwrite benefits. In Nevada: Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. dba HMO Nevada. In New Hampshire: Anthem Health Plans of New Hampshire, Inc. HMO plans are administered by Anthem Health Plans of New Hampshire, Inc. and underwritten by Matthew Thornton Health Plan, Inc. In Ohio: Community Insurance Company. In Virginia: Anthem Health Plans of Virginia, Inc. trades as Anthem Blue Cross and Blue Shield in Virginia, and its service area is all of Virginia except for the City of Fairfax, the Town of Vienna, and the area east of State Route 123. In Wisconsin: Blue Cross Blue Shield of Wisconsin (BCBSWI), which underwrites or administers the PPO and indemnity policies and underwrites the out of network benefits in POS policies offered by CompCare or WCIC; CompCare Health Services Insurance Corporation (CompCare) underwrites or administers the HMO policies and Wisconsin Collaborative Insurance Company (WCIC) underwrites or administers Well

Priority HMO or POS policies. Independent licensees of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. Use of the Anthem websites constitutes your agreement with our Terms of Use.
